Who is sponsoring NCT04195711?

NCT04195711 is sponsored by Alaska Blind Child Discovery.

What drugs are being tested in NCT04195711?

Interventions in NCT04195711: objective pediatric vision screen, "blinq,".

What condition does NCT04195711 study?

NCT04195711 studies Strabismic Amblyopia, Refractive Amblyopia, Strabismus.

Is NCT04195711 still recruiting?

NCT04195711 is currently completed. Last updated 19 October 2020.

Last reviewed 2020-10-19 · How we verify

NCT04195711

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparative Validation of "Blinq" and "2WIN" Vision Screeners

Completed Last updated 19 October 2020

What this trial tests

trial testing objective pediatric vision screen, "blinq," in Strabismic Amblyopia in 100 participants. Completed in 26 November 2019.

Timeline

18 November 2019

Primary endpoint
26 November 2019

26 November 2019

Quick facts

Lead sponsor	Alaska Blind Child Discovery
Status	Completed
Study type	OBSERVATIONAL
Enrollment	100
Start date	18 November 2019
Primary completion	26 November 2019
Estimated completion	26 November 2019
Sites	1 location across United States

Drugs / interventions tested

objective pediatric vision screen, "blinq,"

Conditions studied

Strabismic Amblyopia — all drugs for Strabismic Amblyopia →
Refractive Amblyopia — all drugs for Refractive Amblyopia →
Strabismus — all drugs for Strabismus →

Sponsor

Alaska Blind Child Discovery

Who can join

Adults 1 to 65, any sex, with Strabismic Amblyopia or Refractive Amblyopia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

After 28 years of development, the binocular birefringence screener ("blinq," "Rebion") was commercially released. It need to be validated with AAPOS (American Association for Pediatric Ophthalmology and Strabismus) criteria in part because the next Uniform Standards document is pending. Adult and children pediatric and strabismus patients were screened with blinq and "2WIN" photoscreener with "CR" corneal reflex alignment test and then compared to confirmatory exam with age-appropriate determination of binocular status.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Comparative AAPOS Validation of the Birefringent Amblyopia Screener with Isolated Small-Angle Strabismus.
Arnold RW. · · 2020 · cited 13× · PMID 32099317 · DOI 10.2147/opth.s242335

Verify or expand the search:

Other Alaska Blind Child Discovery trials

Trials by the same sponsor.

NCT06165705 — Treating Amblyopia With CureSight · NA · unknown
NCT04249505 — Refractive Accuracy of "2WIN" and Portable Autorefractors · completed
NCT04297969 — Hyperopia Detection GCK With Glow Fixation · completed
NCT04068129 — Enhanced Housing Photoscreeners 2WIN and GoCheckKids Compared in Burma and Alaska · completed
NCT03668067 — Performance of 2WIN Photoscreener With Corneal Reflex Compared to School Bus Retinoscopy by AAPOS Guidelines · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04195711 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Alaska Blind Child Discovery
Last refreshed: 19 October 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04195711.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing